Alnylam Pharmaceuticals (ALNY) Competitors $438.46 +3.36 (+0.77%) Closing price 03:59 PM EasternExtended Trading$438.54 +0.09 (+0.02%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALNY vs. AMGN, GILD, VRTX, REGN, BIIB, INCY, UTHR, NBIX, BMRN, and EXELShould you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry. Alnylam Pharmaceuticals vs. Its Competitors Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Biogen Incyte United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Alnylam Pharmaceuticals (NASDAQ:ALNY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Do institutionals and insiders hold more shares of ALNY or AMGN? 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 0.8% of Amgen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, ALNY or AMGN? Alnylam Pharmaceuticals has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Which has higher valuation & earnings, ALNY or AMGN? Amgen has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B25.56-$278.16M-$2.47-177.51Amgen$33.42B4.63$4.09B$12.2323.56 Does the media prefer ALNY or AMGN? In the previous week, Amgen had 60 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 104 mentions for Amgen and 44 mentions for Alnylam Pharmaceuticals. Amgen's average media sentiment score of 1.08 beat Alnylam Pharmaceuticals' score of 0.80 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 13 Very Positive mention(s) 6 Positive mention(s) 19 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 62 Very Positive mention(s) 8 Positive mention(s) 18 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Is ALNY or AMGN more profitable? Amgen has a net margin of 18.96% compared to Alnylam Pharmaceuticals' net margin of -12.96%. Amgen's return on equity of 174.71% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.96% -273.52% -7.39% Amgen 18.96%174.71%13.12% Do analysts prefer ALNY or AMGN? Alnylam Pharmaceuticals presently has a consensus price target of $403.92, suggesting a potential downside of 7.88%. Amgen has a consensus price target of $303.76, suggesting a potential upside of 5.44%. Given Amgen's higher probable upside, analysts plainly believe Amgen is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 23 Buy rating(s) 0 Strong Buy rating(s) 2.85Amgen 2 Sell rating(s) 11 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.33 SummaryAmgen beats Alnylam Pharmaceuticals on 12 of the 17 factors compared between the two stocks. Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNY vs. The Competition Export to ExcelMetricAlnylam PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.47B$2.98B$5.45B$9.67BDividend YieldN/A2.46%3.99%4.14%P/E Ratio-177.5117.8930.0425.01Price / Sales25.56174.35377.6078.24Price / CashN/A41.8335.9458.58Price / Book229.567.278.135.68Net Income-$278.16M-$54.43M$3.25B$265.58M7 Day Performance9.12%-0.07%1.09%2.50%1 Month Performance38.10%5.07%2.75%1.87%1 Year Performance62.12%10.31%28.40%24.05% Alnylam Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNYAlnylam Pharmaceuticals3.9023 of 5 stars$438.46+0.8%$403.92-7.9%+67.2%$57.47B$2.25B-177.512,230Analyst ForecastAMGNAmgen4.5779 of 5 stars$301.94+1.7%$307.27+1.8%-8.9%$162.36B$33.42B27.5528,000Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastAnalyst RevisionGILDGilead Sciences4.657 of 5 stars$114.51+1.2%$112.36-1.9%+49.0%$142.44B$28.75B24.1117,600Trending NewsEarnings ReportAnalyst UpgradeGap UpVRTXVertex Pharmaceuticals4.9232 of 5 stars$472.27+2.2%$509.89+8.0%-19.4%$121.28B$11.10B-120.486,100Trending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst RevisionREGNRegeneron Pharmaceuticals4.9077 of 5 stars$571.54+2.3%$832.73+45.7%-47.6%$61.70B$14.20B14.4015,106Positive NewsEarnings ReportDividend AnnouncementAnalyst RevisionBIIBBiogen4.9106 of 5 stars$132.20+0.2%$185.63+40.4%-36.1%$19.38B$9.68B12.647,605INCYIncyte4.771 of 5 stars$78.04+3.2%$79.73+2.2%+29.7%$15.24B$4.58B17.742,617Analyst UpgradeUTHRUnited Therapeutics4.9572 of 5 stars$292.65-0.6%$379.69+29.7%-7.1%$13.20B$2.88B11.421,305NBIXNeurocrine Biosciences4.9668 of 5 stars$128.04-0.7%$160.90+25.7%-12.9%$12.70B$2.36B37.881,800BMRNBioMarin Pharmaceutical4.9941 of 5 stars$60.31+3.7%$93.74+55.4%-31.1%$11.57B$2.95B22.423,040Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeEXELExelixis4.9476 of 5 stars$36.81-1.2%$44.44+20.7%+41.0%$9.91B$2.23B17.701,147Positive News Related Companies and Tools Related Companies Amgen Alternatives Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Exelixis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALNY) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALNY Stock Alerts